Overview A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma Status: Terminated Trial end date: 2009-10-01 Target enrollment: Participant gender: Summary To evaluate the antitumor activity of IPI-504 in patients with metastatic melanoma. Phase: Phase 2 Details Lead Sponsor: Infinity Pharmaceuticals, Inc.